Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma

Bone Marrow Transplantation

Volumn 51, Issue 3, 2016, Pages 432-434

  Haji, S ^a   Kiyasu, J ^b,c   Choi, I ^a   Suehiro, Y ^a   Toyoda, K ^a   Tsuda, M ^a   Takamatsu, A ^a   Nakashima, Y ^a   Miyoshi, H ^b   Shiratsuchi, M ^d   Yamasaki, S ^e   Uike, N ^a   Abe, Y ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ASO IIZUKA HOSPITAL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; MOGAMULIZUMAB; MYCOPHENOLATE MOFETIL; OXALIPLATIN; PREDNISOLONE; SOBUZOXANE; TACROLIMUS; VINCRISTINE; CCR4 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR4; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE PANCREATITIS; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER SURVIVAL; CASE REPORT; CERVICAL LYMPH NODE; CERVICAL LYMPHADENOPATHY; CHRONIC GRAFT VERSUS HOST DISEASE; CONTINUOUS INFUSION; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; LETTER; LYMPHADENOPATHY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL LEUKEMIA; THROMBOCYTE COUNT; ALLOGRAFT; BONE MARROW TRANSPLANTATION; LEUKEMIA-LYMPHOMA, ADULT T-CELL;

ALLOGRAFTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; RECEPTORS, CCR4;

EID: 84959560630     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.254     Document Type: Letter

References (15)

1. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458-5464.
2. Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010; 116: 1369-1376.
3. Choi I, Tanosaki R, Uike N, Utsunomiya A, Tomonaga M, Harada M et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant 2011; 46: 116-118.
4. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemialymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-842.
5. Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol 2015; 169: 672-682.
6. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001; 194: 847-853.
7. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One 2009; 4: e4420.
8. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
9. Okamoto T, Nishimura Y, Yamada S, Yamada S, Itoh T, Mori A et al. Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma. Acta Haematol 2000; 104: 128-130.
10. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389-399.
11. Martin PJ, Pei J, Gooley T, Anasetti C, Appelbaum FR, Deeg J et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant 2004; 10: 552-560.
12. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 2010; 120: 1479-1493.
13. Motohashi K, Suzuki T, Kishimoto K, Numata A, Nakajima Y, Tachibana T et al. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation. Int J Hematol 2013; 98: 258-260.
14. Ito Y, Miyamoto T, Chong Y, Aoki T, Kato K, Akashi K et al. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation. Bone Marrow Transplant 2013; 48: 998-999.
15. Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood 2012; 119: 2141-2148.